Search

Your search keyword '"Gafter‐Gvili, Anat"' showing total 895 results
Start Over Author "Gafter‐Gvili, Anat"
895 results on '"Gafter‐Gvili, Anat"'

36. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis

Author

Vidal, Liat, Gafter-Gvili, Anat, Salles, Gilles, Bousseta, Sami, Oberman, Bernice, Rubin, Carmit, van Oers, Marinus H.J., Fortpied, Catherine, Ghielmini, Michele, Pettengell, Ruth, Witzens-Harig, Mathias, Dreger, Peter, Vitolo, Umberto, Gomes da Silva, Maria, Evangelista, Andrea, Li, Hailun, Freedman, Laurence, Habermann, Thomas M., and Shpilberg, Ofer

Published
2017
Full Text
View/download PDF

44. A Case of Rickettsiosis in a Patient with Glucose-6-Phosphate Dehydrogenase (G6pd) Deficiency

Author

Garin-kol Avrahami Reut, Zerbib Olivier, Gafter Gvili Anat, Lev Shaul, Gal Sahaf Levin, and Gottesman Tamar

Abstract

Rickettsia is a group of Gram-negative intra cellular obligatory bacteria. Rickettsia species are an important cause of infectious disease in people and animals. Fleas, ticks, mite, lice etc., serve as vectors who transfer the rickettsia from animal to humans.Rickettsiosis is one of the oldest known vector-borne diseases(Blanda et al., 2020). Usually it is a nonspecific self-limiting febrile illness without major complications. Fever, headache, mild-rash, myalgia's and anorexia are the most common presenting signs and symptoms. Laboratory findings include elevated transaminase levels, hyponatremia, thrombocytopenia and anemia (Merhej et al., 2014). The disease is usually of benign nature. Severe complications are reported in about 6% of cases. Patients may present with organ involvement, severe vasculitis and multi organ failure (Oteo and Portillo, 2012) and the mortality rate is up to 2.5%(Giammanco et al., 2005; Raoult et al., 1986).

Published
2022

46. Extracorporeal photopheresis induces NETosis in neutrophils derived from patients with chronic graft‐vs‐host disease.

Author

Goldberg, Idan, Granot, Galit, Telerman, Alona, Partouche, Shirly, Shochat, Tzippy, Halperin, Erez, Gafter‐Gvili, Anat, Shargian, Liat, Yeshurun, Moshe, Raanani, Pia, Wolach, Ofir, and Yahalom, Vered

Subjects
GRAFT versus host disease, CHRONICALLY ill, LEUCOCYTE elastase, NEUTROPHILS
Abstract

Introduction: Extracorporeal photopheresis (ECP) is considered an effective treatment for patients with chronic graft vs host disease (cGVHD) and demonstrates efficacy in ameliorating GVHD. The mechanism by which ECP acts against cGVHD is not fully understood. Preliminary observations have hinted at the potential involvement of neutrophil extracellular traps (NETs) formation in the pathogenesis of cGVHD. We aimed to assess the influence of ECP on the formation of NETs in patients with cGVHD as a potential mechanism in this setting. Methods: Patients treated with ECP for cGVHD at the Rabin Medical Center were included in this study. Blood samples were obtained at three different time points: before starting an ECP cycle, at the end of the first day of treatment, and 24 h following the initiation of the ECP treatment cycle. Neutrophils were harvested from all blood samples. NET formation was assessed by measurement of NET‐bound specific neutrophil elastase activity and by immunofluorescence staining. Results: Six patients (two females and four males) with cGVHD were included in the study. We observed a significant increase in NET formation among all six patients following ECP. Net‐bound specific neutrophil elastase activity was elevated from a median value of 2.23 mU/mL (interquartile range [IQR] 2.06‐2.47 mU/mL) at baseline to a median value of 13.06 mU/mL (IQR 10.27‐15.97 mU/mL) immediately after the treatment and to a peak median value of 14.73 mU/mL (IQR 9.6‐22.38 mU/mL) 24 h following the initiation of the ECP cycle. A qualitative assessment of NET formation using immunofluorescence staining has demonstrated markedly increased expression of citrullinated histone H3, a marker of NET formation, following ECP treatment. Conclusions: Our preliminary data indicate that ECP induces NET formation among patients with cGVHD. The contribution of increased NET formation to the therapeutic effect of cGVHD should be further investigated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome

Author

Ofran, Yishai, Filanovsky, Kalman, Gafter-Gvili, Anat, Vidal, Liat, Aviv, Ariel, Gatt, Moshe E., Silbershatz, Itay, Herishanu, Yair, Arad, Ariela, Tadmor, Tamar, Dally, Najib, Nemets, Anatoly, Rouvio, Ory, Ronson, Aharon, Herzog-Tzarfati, Katrin, Akria, Luiza, Braester, Andrei, Hellmann, Ilana, Yeganeh, Shay, Nagler, Arnon, Leiba, Ronit, Mittelman, Moshe, and Merkel, Drorit

Published
2015
Full Text
View/download PDF

49. A Systematic Review Assessing the Underrepresentation of Cancer Patients in COVID-19 Trials

Author

Buchrits, Shira, Fredman, Danielle, Ben Tikva Kagan, Kim, and Gafter-Gvili, Anat

Subjects
Systematic Review, Hematology, General Medicine
Abstract

Background: The new severe acute respiratory syndrome coronavirus 2 has emerged as a global pandemic that threatens thousands around the world. Observational cohort studies have demonstrated that cancer patients have inferior outcomes due to underlying malignancy, treatment-related immunosuppression, or increased comorbidities. We aimed to examine the representation of cancer patients (hematological malignancies and solid tumors) in COVID-19 therapeutic and prophylactic interventional trials. Methods: In this review, all randomized controlled trials (RCTs) published between December 2019 and August 2021 were included. We included only trials evaluating medications that were recommended by NIH guidelines: steroids, tocilizumab, remdesivir, and REGN-COV2. Results: The search yielded 541 potentially relevant RCTs, 22 of which were considered suitable. All trials included patients with solid cancer and hematological malignancies in the formal reported inclusion criteria. However, only two trials reported the accurate number of cancer patients included. Ten trials excluded neutropenic patients and seven trials excluded thrombocytopenic patients. Eleven trials excluded patients that were treated with any immunosuppression treatment. None of the two trials that included cancer patients reported separate outcomes for this population. Conclusion: Our systematic review shows that cancer patients are underrepresented in COVID-19 interventional therapeutic trials, and evidence regarding outcomes are lacking.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results